PCI Biotech Holding Past Earnings Performance
Past criteria checks 0/6
PCI Biotech Holding has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 21.7% per year.
Key information
19.0%
Earnings growth rate
19.5%
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | -21.7% |
| Return on equity | -49.9% |
| Net Margin | -265.2% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Aug 05
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully
Apr 21We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely
Dec 16We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Apr 09What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?
Feb 15PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans
Dec 22
Revenue & Expenses Breakdown
How PCI Biotech Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6 | -16 | 9 | 15 |
| 31 Mar 24 | 4 | -18 | 9 | 16 |
| 31 Dec 23 | 3 | -20 | 10 | 16 |
| 30 Sep 23 | 3 | -23 | 11 | 17 |
| 30 Jun 23 | 3 | -29 | 14 | 19 |
| 31 Mar 23 | 4 | -38 | 17 | 26 |
| 31 Dec 22 | 5 | -55 | 16 | 45 |
| 30 Sep 22 | 5 | -73 | 17 | 61 |
| 30 Jun 22 | 5 | -84 | 16 | 73 |
| 31 Mar 22 | 6 | -88 | 17 | 77 |
| 31 Dec 21 | 6 | -88 | 21 | 72 |
| 30 Sep 21 | 7 | -90 | 19 | 72 |
| 30 Jun 21 | 7 | -90 | 18 | 74 |
| 31 Mar 21 | 7 | -100 | 18 | 77 |
| 31 Dec 20 | 7 | -72 | 14 | 76 |
| 30 Sep 20 | 8 | -71 | 18 | 76 |
| 30 Jun 20 | 8 | -64 | 16 | 74 |
| 31 Mar 20 | 9 | -61 | 14 | 82 |
| 31 Dec 19 | 9 | -89 | 15 | 83 |
| 30 Sep 19 | 10 | -68 | 15 | 73 |
| 30 Jun 19 | 10 | -62 | 14 | 64 |
| 31 Mar 19 | 10 | -43 | 14 | 44 |
| 31 Dec 18 | 10 | -35 | 14 | 40 |
| 30 Sep 18 | 10 | -46 | 13 | 43 |
| 30 Jun 18 | 10 | -48 | 14 | 44 |
| 31 Mar 18 | 10 | -48 | 13 | 45 |
| 31 Dec 17 | 10 | -43 | 13 | 41 |
| 30 Sep 17 | 10 | -34 | 10 | 35 |
| 30 Jun 17 | 10 | -33 | 8 | 36 |
| 31 Mar 17 | 10 | -35 | 6 | 40 |
| 31 Dec 16 | 10 | -32 | 4 | 39 |
| 30 Sep 16 | 11 | -34 | 4 | 41 |
| 30 Jun 16 | 11 | -34 | 4 | 41 |
| 31 Mar 16 | 10 | -31 | 4 | 38 |
| 31 Dec 15 | 10 | -32 | 4 | 39 |
| 30 Sep 15 | 9 | -34 | 5 | 38 |
| 30 Jun 15 | 8 | -33 | 4 | 38 |
| 31 Mar 15 | 8 | -34 | 4 | 39 |
| 31 Dec 14 | 7 | -36 | 4 | 39 |
| 30 Sep 14 | 8 | -35 | 4 | 40 |
| 30 Jun 14 | 8 | -33 | 4 | 38 |
| 31 Mar 14 | 7 | -30 | 4 | 35 |
| 31 Dec 13 | 7 | -28 | 3 | 33 |
Quality Earnings: PCIB is currently unprofitable.
Growing Profit Margin: PCIB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCIB is unprofitable, but has reduced losses over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare PCIB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCIB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: PCIB has a negative Return on Equity (-49.87%), as it is currently unprofitable.